Eli Lilly’s Mounjaro and Zepbound Deliver $36.5B in 2025 Sales
Eli Lilly’s Mounjaro and Zepbound posted combined sales of $36.5 billion in 2025, underpinning the drugmaker’s leading revenue streams. The company benefits from strong pipeline innovation and M&A-driven expansion but faces headwinds from patent cliffs and pricing uncertainty.
1. Mounjaro and Zepbound Drive 2025 Revenue Growth
Eli Lilly achieved combined 2025 sales of $36.5 billion from Mounjaro and Zepbound, with demand rising rapidly and supporting a broader industry recovery in large-cap pharmaceuticals.
2. Strong R&D and M&A Priorities
The company allocates a significant portion of its revenues to R&D, integrates AI technologies to accelerate drug discovery and pursues acquisitions of smaller biotech firms to bolster its pipeline across oncology, rare diseases and metabolic therapies.
3. Patent Expirations and Pricing Uncertainty
Eli Lilly faces upcoming patent cliffs on key treatments, potential generic competition and pressure from ongoing pricing negotiations, which could temper future top-line growth despite its current momentum.